Amedisys (AMED) Tops Q4 EPS by 1c

Amedisys (NASDAQ: AMED) reported Q4 EPS of $0.27, $0.01 better than the analyst estimate of $0.26. Revenue for the quarter came in at $300.5 million versus the consensus estimate of $301.62 million.

Paul B. Kusserow, President and Chief Executive Officer stated, "Amedisys made great strides in 2014 resulting in stabilized operations and improved financial performance while remaining focused on providing high-quality patient care. I am particularly proud of the way our employees and leadership team responded to the challenges in front of them. I am fortunate to have the opportunity to lead a great organization with such a critical mission, and I look forward to the opportunities in front of us."

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook